China, rare diseases and affordability: How riders in Congress may shape FDA's user fees

FDA's deputy commissioner tells DIA attendees the Trump administration will keep pursuing Makary's user fee priorities as Congress weighs bipartisan riders on clinical trials, China competition and rare diseases.

Raccontata daendpoints.news